GlassScriptPhysician profile
Martin H Kay
NPI 1750450615
$21,683.28
in general payments reported to CMS, 2019-2025
40 companies · $3,373 in 2025
The $3,373 reported for 2025 was more than what 86% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,230 · 2020: $1,757 · 2021: $2,242 · 2022: $3,861 · 2023: $3,789 · 2024: $4,432 · 2025: $3,373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $415 · Travel and Lodging: $3.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,175.77 |
| Education | $414.61 |
| Travel and Lodging | $3.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,093.79 | 2019-2025 | |
| Janssen Biotech, INC. | $2,473.75 | 2019-2025 | Tremfya |
| Genzyme Corporation | $1,652.00 | 2019-2025 | |
| Lilly USA, LLC | $1,577.24 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $1,397.69 | 2019-2025 | Ilumya, Winlevi |
| Merz North America, INC. | $1,372.33 | 2019-2024 | Xeomin |
| Pfizer INC. | $1,007.49 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $940.70 | 2019-2025 | Dupixent, Libtayo |
| Ucb, INC. | $919.10 | 2019-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $903.57 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $810.76 | 2019-2025 | Siliq, Duobrii, Cabtreo |
| Leo Pharma INC. | $772.18 | 2019-2025 | Adbry, Anzupgo |
| Amgen INC. | $718.49 | 2019-2025 | Otezla, Otezla |
| Incyte Corporation | $717.56 | 2021-2025 | Opzelura, Opzelura |
| Galderma Laboratories, L.P. | $620.52 | 2019-2025 | Nemluvio, Aklief, Dysport |
Show all 39 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Kay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.